References of "LUTTERI, Laurence"
     in
Bookmark and Share    
Full Text
See detailAuto-immune gastritis characteristics in a large series of patients with auto-immune thyroiditis.
VALDES SOCIN, Hernan Gonzalo ULg; TOME, M.; LUTTERI, Laurence ULg et al

in XXIVth Belgian Week of Gastroenterology 2012 - Abstract book (2012)

Detailed reference viewed: 47 (7 ULg)
Full Text
Peer Reviewed
See detailComparison of the platelet concentrations obtained in platelet-rich plasma (PRP) between the GPS™ II and GPS™ III systems
Kaux, Jean-François ULg; Le Goff, Caroline ULg; Renouf, Julien et al

in Pathologie Biologie (2011), 59(5), 275-277

Introduction Platelet growth factors are known for their ability to speed up tissue healing (bone, skin, tendons, muscle). Various techniques make it possible to collect this platelet-rich plasma or PRP ... [more ▼]

Introduction Platelet growth factors are known for their ability to speed up tissue healing (bone, skin, tendons, muscle). Various techniques make it possible to collect this platelet-rich plasma or PRP. Methods This study compares the platelet concentrations obtained from five patients using GPS™ III, which has recently come onto the market, with those obtained using GPS™ II. Results and conclusion We obtain a platelet concentration that is six to nine times greater with GPS ™ II and GPS™ III, but there is no significant difference between the concentrations of PRP obtained with the two systems. [less ▲]

Detailed reference viewed: 101 (25 ULg)
Full Text
Peer Reviewed
See detailGPS™ II and GPS™ III: comparison of obtained platelets concentrations
Kaux, Jean-François ULg; Le Goff, Caroline ULg; Renouf, Julien et al

Poster (2010, March 20)

Introduction: Recently, several researches, essentially in vitro, demonstrated the positive effects of platelets on healing process of different tissues: bones, muscles and tendons. The aim of this study ... [more ▼]

Introduction: Recently, several researches, essentially in vitro, demonstrated the positive effects of platelets on healing process of different tissues: bones, muscles and tendons. The aim of this study is to compare the obtained platelets concentration between the new GPS™ III and GPS™ II. Methods: Two blood samples of 52 mL were taken in 5 volunteers and transferred respectively in both GPS™ II and GPS™ III. These devices were centrifuged at 3200 RPM during 15 min. The platelet-rich plasma (PRP) was thus collected and transferred in 6 mL test tubes. Cells count was done using an analyser ABX Micros 60. Results and conclusion: Platelets concentrations were more important from 6.2 up to 9.2 times with GPS™ II and from 7.3 up to 8.3 times with GPS™ III compared to blood samples. Efficiency of the collected platelets was around 92% for GPS™ II and 96% for GPS™ III. Both techniques made it possible to collect platelets but, unfortunately, also a lot of red and white blood cells. None of these parameters showed any significant difference (p>0.05). Conflicts of interests: The 10 devices GPS™ II and GPS™ III were provided gracefully by the firm Biomet Biologics TTC. [less ▲]

Detailed reference viewed: 110 (16 ULg)
Full Text
Peer Reviewed
See detailAnticorps anti-gliadines déamidées et maladie coeliaque : données actuelles et évaluation des faux positifs de cinq trousses de dosage
Lutteri, Laurence ULg; Sagot, Laurence; Chapelle, Jean-Paul ULg

in Annales de Biologie Clinique (2010), 68(2), 149-56

Recently, anti-deamidated gliadin antihodies were proposed for the serological diagnosis of celiac disease. We evaluate the specificity of different anti-deamidated gliadin antibodies ELISA in comparison ... [more ▼]

Recently, anti-deamidated gliadin antihodies were proposed for the serological diagnosis of celiac disease. We evaluate the specificity of different anti-deamidated gliadin antibodies ELISA in comparison with conventional anti-native gliadin kits. Serum sainples froin 46 non celiac patients trere analyzed by five different quantitative ELISA for anti-native gliadin, antideamidated gliadin and anti-fransglutaininase neo-epitope antibodies together with a screening ELISA. Twenty-four percent of the patients deinonstrated anti-native gliadin lgA and 63% 1gO antibodies. Using anti-dearnidated gliadin antibodies, tire number of false positive IgA and, particularly, 1gG results,markedly decreased in the non celiac patients: 21 and 24% respectively with anti-Gliadin (GAF-3X) Euroimmun kit, 7 and 26% with Bindazyme 1-lurnan Anti-Gliadin (MGP) The Binding Site kit and 0 and 41% with Celiac G+ Immco kit. The new assay which makes use of the physiological complex of tissue transglutaminase cross-linked with deamidated gliadin peptides, called neo-epitope, did not improve the differential diagnosis of celiac disease with 30% of false positive results in IgG (2% in IgA). IJsing the Inova screening kit, a positive resuit for IgA and/or IgG anti-deamidated gliadin and!or anti- tissue transglutaminase antibodies was obtained in 24% of the non celiac patients. In conclusion, our study assessed the superiority, in ternis of specificity, of anti-deamidated gliadin antibodies, over the conventional anti-gliadin antibodies for die differential diagnosis of celiac disease. [less ▲]

Detailed reference viewed: 699 (19 ULg)
Full Text
Peer Reviewed
See detailIntérêt des anticorps monoclonaux dans le laboratoire d'analyses biomédicales
Mistretta, Virginie ULg; Cavalier, Etienne ULg; Collette, Julien ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 257-263

Detailed reference viewed: 54 (7 ULg)
Full Text
Peer Reviewed
See detailDiscrepancies between creatinine-based and cystatin C-based equations in estimating prevalence of stage 3 chronic kidney disease in an elderly population.
Delanaye, Pierre ULg; Cavalier, Etienne ULg; Saint-Remy, Annie ULg et al

in Scandinavian Journal of Clinical & Laboratory Investigation (2009), 69(3), 344-9

Background . The prevalence of stage 3 chronic kidney disease (CKD) is increasing, calculated using the modification of diet in renal disease (MDRD) study equation for estimating glomerular filtration ... [more ▼]

Background . The prevalence of stage 3 chronic kidney disease (CKD) is increasing, calculated using the modification of diet in renal disease (MDRD) study equation for estimating glomerular filtration rate (GFR). Cystatin C-based equations are also being used to estimate GFR. Using creatinine-based and cystatin C-based equations, the aim of our study was to measure the difference in prevalence of stage 3 CKD in a population. Methods . CKD screening is organized in the Province of Liege, Belgium. On a voluntary basis, people aged between 45 and 75 years are invited for screening. GFR is estimated using the MDRD study equation and by the three recent cystatin C-based equations proposed by Levey's group. The Levey 1 equation is based on cystatin C only and the Levey 2 equation on cystatin C corrected for age and sex. The Levey 3 equation combines cystatin C, creatinine, age and sex. Results . The population screened comprised 754 people. Cystatin C is highly correlated with creatinine (r = 0.6196, p<0.0001). Prevalence of stage 3 CKD when GFR is estimated by the MDRD equation study is 17.2 %, which is significantly and much higher than the prevalence obtained when cystatin C-based equations are used. Indeed, prevalence is 2 %, 3.3 % and 5.8 % with the Levey 1, 2 and 3 equations, respectively. Conclusions . The prevalence of stage 3 CKD varies strongly following the method used for estimating GFR, creatinine-based or cystatin C-based equations. Such discrepancies must be confirmed and explained in additional studies using GFR measured with a reference method. [less ▲]

Detailed reference viewed: 41 (4 ULg)
Full Text
Peer Reviewed
See detailEtude analytique des trois trousses de cystatine C et impact sur les formules basées sur la cystatine pour l'estimation du DFG.
Cavalier, Etienne ULg; Péroni, Laurence; Abshoff, Christelle et al

in Néphrologie & Thérapeutique (2008, November), 4(6), 399-400

Detailed reference viewed: 50 (8 ULg)
Full Text
Peer Reviewed
See detailComment j'explore... Revue des principaux auto-anticorps
Le Goff, Caroline ULg; Kaux, Jean-François ULg; Chapelle, Jean-Paul ULg et al

in Revue Médicale de Liège (2008), 63(1), 43-9

Auto-immune diseases represent the 3rd cause of morbidity after cardiovascular and oncologic diseases. They often occur in young subjects. Their presence is not synonymous of disease and must be ... [more ▼]

Auto-immune diseases represent the 3rd cause of morbidity after cardiovascular and oncologic diseases. They often occur in young subjects. Their presence is not synonymous of disease and must be associated to clinical signs to be pathological. However, their discovery can require a complement of investigations and the possibility of a follow-up because some auto-antibodies are predictive of disease. This paper is concerned with the main autoantibodies that can be picked out at the laboratory of immunology. Some technical explanations and INAMI rules are explained too. [less ▲]

Detailed reference viewed: 294 (24 ULg)
Full Text
Peer Reviewed
See detailImpact de la stabilité de la cystatine C sur la validité des mesures dans les études rétrospectives
Piéroni, Laurence; Delanaye, Pierre ULg; Abshoff, Christelle et al

Poster (2008)

Detailed reference viewed: 53 (10 ULg)
Full Text
Peer Reviewed
See detailProteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study.
Meuwis, Marie-Alice ULg; Fillet, Marianne ULg; Lutteri, Laurence ULg et al

in Clinical Biochemistry (2008), 41(12), 960-7

OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict ... [more ▼]

OBJECTIVES: Infliximab is the first anti-TNFalpha accepted by the Food and Drug Administration for use in inflammatory bowel disease treatment. Few clinical, biological and genetic factors tend to predict response in Crohn's disease (CD) patient subcategories, none widely predicting response to infliximab. DESIGN AND METHODS: Twenty CD patients showing clinical response or non response to infliximab were used for serum proteomic profiling on Surface Enhanced Lazer Desorption Ionisation-Time of Flight-Mass Spectrometry (SELDI-TOF-MS), each before and after treatment. Univariate and multivariate data analysis were performed for prediction and characterization of response to infliximab. RESULTS: We obtained a model of classification predicting response to treatment and selected relevant potential biomarkers, among which platelet aggregation factor 4 (PF4). We quantified PF4, sCD40L and IL-6 by ELISA for correlation studies. CONCLUSIONS: This first proteomic pilot study on response to infliximab in CD suggests association between platelet metabolism and response to infliximab and requires validation studies on a larger cohort of patients. [less ▲]

Detailed reference viewed: 134 (26 ULg)
Full Text
Peer Reviewed
See detailMonomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis
De Seny, Dominique ULg; Fillet, Marianne ULg; Ribbens, Clio ULg et al

in Clinical Chemistry (2008), 54

BACKGROUND: SELDI-TOF mass spectrometry (MS) is a high-throughput proteomic approach with potential for identifying novel forms of serum biomarkers of arthritis. METHODS: We used SELDI-TOF MS to analyze ... [more ▼]

BACKGROUND: SELDI-TOF mass spectrometry (MS) is a high-throughput proteomic approach with potential for identifying novel forms of serum biomarkers of arthritis. METHODS: We used SELDI-TOF MS to analyze serum samples from patients with various forms of inflammatory arthritis. Several protein profiles were collected on different Bio-Rad Laboratories ProteinChip arrays (CM10 and IMAC-Cu(2+)) and were evaluated statistically to select potential biomarkers. RESULTS: SELDI-TOF MS analyses identified several calgranulin proteins [S100A8 (calgranulin A), S100A9 (calgranulin B), S100A9*, and S100A12 (calgranulin C)], serum amyloid A (SAA), SAA des-Arg (SAA-R), and SAA des-Arg/des-Ser (SAA-RS) as biomarkers and confirmed the results with other techniques, such as western blotting, immunoprecipitation, and nano-LC-MS/MS. The S100 proteins were all able to significantly differentiate samples from patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) from those of patients with inflammatory bowel diseases used as an inflammatory control (IC) group, whereas the SAA, SAA-R, and SAA-RS proteins were not, with the exception of AS. The 4 S100 proteins were coproduced in all of the pathologies and were significantly correlated with the plasma calprotectin concentration; however, these S100 proteins were correlated with the SAA peak intensities only in the RA and IC patient groups. In RA, these S100 proteins (except for S100A12) were significantly correlated with the serum concentrations of C-reactive protein, matrix metalloproteinase 3, and anti-cyclic citrullinated peptide and with the Disease Activity Score (DAS(28)). CONCLUSIONS: The SELDI-TOF MS technology is a powerful approach for analyzing the status of monomeric, truncated, or posttranslationally modified forms of arthritis biomarkers, such as the S100A8, S100A9, S100A12, and SAA proteins. The fact that the SELDI-TOF MS data were correlated with results obtained with the classic calprotectin ELISA test supports the reliability of this new proteomic technique. [less ▲]

Detailed reference viewed: 66 (22 ULg)